SK157599A3 - Method and compositions for administering taxanes orally to human patients - Google Patents

Method and compositions for administering taxanes orally to human patients Download PDF

Info

Publication number
SK157599A3
SK157599A3 SK1575-99A SK157599A SK157599A3 SK 157599 A3 SK157599 A3 SK 157599A3 SK 157599 A SK157599 A SK 157599A SK 157599 A3 SK157599 A3 SK 157599A3
Authority
SK
Slovakia
Prior art keywords
paclitaxel
taxane
cyclosporin
oral
meleu
Prior art date
Application number
SK1575-99A
Other languages
English (en)
Slovak (sk)
Inventor
Samuel Broder
Kenneth L Duchin
Sami Selim
Original Assignee
Baker Norton Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Norton Pharma filed Critical Baker Norton Pharma
Publication of SK157599A3 publication Critical patent/SK157599A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK1575-99A 1997-05-27 1998-04-22 Method and compositions for administering taxanes orally to human patients SK157599A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86351397A 1997-05-27 1997-05-27
PCT/US1998/007776 WO1998053811A1 (fr) 1997-05-27 1998-04-22 Methodes et compositions d'administration de taxanes par voie orale a des humains

Publications (1)

Publication Number Publication Date
SK157599A3 true SK157599A3 (en) 2002-10-08

Family

ID=25341241

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1575-99A SK157599A3 (en) 1997-05-27 1998-04-22 Method and compositions for administering taxanes orally to human patients

Country Status (23)

Country Link
EP (1) EP0994706B1 (fr)
JP (1) JP2002500667A (fr)
KR (1) KR100615783B1 (fr)
CN (2) CN1261275A (fr)
AR (1) AR012731A1 (fr)
AT (1) ATE308365T1 (fr)
AU (1) AU7130098A (fr)
BR (1) BR9809694A (fr)
CA (1) CA2290446C (fr)
CZ (1) CZ9904244A3 (fr)
DE (1) DE69832173T2 (fr)
DK (1) DK0994706T3 (fr)
ES (1) ES2247690T3 (fr)
HK (1) HK1026637A1 (fr)
HU (1) HUP0003546A3 (fr)
IL (2) IL132992A0 (fr)
NO (1) NO995812L (fr)
PL (1) PL337064A1 (fr)
RU (1) RU2205005C2 (fr)
SK (1) SK157599A3 (fr)
UA (1) UA74767C2 (fr)
WO (1) WO1998053811A1 (fr)
ZA (1) ZA984268B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
WO1998058927A1 (fr) * 1997-06-20 1998-12-30 Baker Norton Pharmaceuticals, Inc. Bioprecurseurs solubles de paclitaxel
GB9718903D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
DK1189637T3 (da) 1999-05-17 2006-12-11 Cancer Res Ventures Ltd Produkter til forbedring af biotilgængeligheden for oralt indgivne medikamenter
BR0015149A (pt) * 1999-10-27 2002-10-29 Baker Norton Pharma Método e composições para administração de taxanos oralmente a pacientes humanos
KR20020013174A (ko) * 2000-08-11 2002-02-20 민경윤 경구 흡수율이 낮은 약물의 흡수율을 증가시키기 위한경구용 조성물
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
EP1365759A2 (fr) * 2001-01-18 2003-12-03 PHARMACIA & UPJOHN COMPANY Preparations de microemulsion chimiotherapeutique de paclitaxel presentant une meilleure biodisponibilite orale
SI1372636T1 (sl) * 2001-02-28 2006-12-31 Bristol Myers Squibb Co Metronomsko odmerjanje taksanov za inhibiranje tumorske rasti
UY27185A1 (es) * 2001-02-28 2002-09-30 Bristol Myers Squibb Co Dosificación metronómica de taxanos
US7063977B2 (en) 2001-08-21 2006-06-20 Bristol-Myers Squibb Company Enzymatic resolution of t-butyl taxane derivatives
GB0523659D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
KR20120050928A (ko) * 2009-06-02 2012-05-21 니칸 파마수티컬스, 엘엘씨 질병 치료용의 사람 포르밀 펩타이드 수용체의 길항제
EP4059497A1 (fr) * 2021-03-17 2022-09-21 Dompé farmaceutici S.p.a. C5ar1 inhibiteurs pour le traitement des réactions d'hypersensibilité aux taxanes
US20240180888A1 (en) * 2021-03-17 2024-06-06 Dompe' Farmaceutici Spa C5ar1 inhibitors for treating hypersensitivity reactions to taxanes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
AU665341B2 (en) * 1990-12-18 1996-01-04 Wellcome Foundation Limited, The Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
JP2783680B2 (ja) * 1991-01-11 1998-08-06 ラボラトワール、グラクソ、ソシエテ、アノニム アクリジン誘導体
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
CN1073105C (zh) * 1994-07-26 2001-10-17 因迪纳有限公司 具有抗肿瘤活性的半合成紫杉烷
TW354293B (en) * 1995-06-06 1999-03-11 Bristol Myers Squibb Co Prodrugs of paclitaxel derivatives
JPH11507356A (ja) * 1995-06-07 1999-06-29 アブマックス，インコーポレイティド 経口薬理化合物の生物有用性を高めるためのエッセンシャルオイルの利用
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
CA2221444A1 (fr) * 1996-01-31 1997-08-07 Steven B. Hansel Procede permettant de rendre actifs du point de vue pharmaceutique des taxanes assimilables par voie orale
US6025359A (en) * 1996-06-17 2000-02-15 Eli Lilly And Company Drug resistance and multidrug resistance modulators
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
IL138767A0 (en) * 1998-04-01 2001-10-31 Rtp Pharma Inc Anticancer compositions

Also Published As

Publication number Publication date
NO995812D0 (no) 1999-11-26
EP0994706A4 (fr) 2001-05-16
EP0994706B1 (fr) 2005-11-02
DK0994706T3 (da) 2006-03-06
KR20010013025A (ko) 2001-02-26
AR012731A1 (es) 2000-11-08
RU2205005C2 (ru) 2003-05-27
UA74767C2 (en) 2006-02-15
DE69832173T2 (de) 2006-08-03
AU7130098A (en) 1998-12-30
CA2290446C (fr) 2008-01-29
WO1998053811A1 (fr) 1998-12-03
ES2247690T3 (es) 2006-03-01
PL337064A1 (en) 2000-07-31
DE69832173D1 (de) 2005-12-08
ATE308365T1 (de) 2005-11-15
HUP0003546A3 (en) 2002-12-28
JP2002500667A (ja) 2002-01-08
CN1550231A (zh) 2004-12-01
CA2290446A1 (fr) 1998-12-03
HUP0003546A2 (hu) 2002-11-28
HK1026637A1 (en) 2000-12-22
KR100615783B1 (ko) 2006-08-25
NO995812L (no) 2000-01-25
CZ9904244A3 (cs) 2001-10-17
IL132992A (en) 2006-08-20
IL132992A0 (en) 2001-03-19
EP0994706A1 (fr) 2000-04-26
ZA984268B (en) 1999-06-23
BR9809694A (pt) 2000-10-03
CN1261275A (zh) 2000-07-26

Similar Documents

Publication Publication Date Title
US6730698B2 (en) Method and compositions for administering taxanes orally to human patients
US6818615B2 (en) Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
RU2296561C2 (ru) Способ, лекарственная форма и наборы для повышения пероральной биологической доступности фармацевтических агентов
US6964946B1 (en) Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
SK157599A3 (en) Method and compositions for administering taxanes orally to human patients
AU1104201A (en) Method and compositions for administering taxanes orally to human patients
AU784159B2 (en) Method and compositions for administering taxanes orally to human patients
EP1634607A2 (fr) Procédé, compositions et kits destinés à améliorer la biodisponibilité par voie orale d'agents pharmaceutiques
KR100563824B1 (ko) 제약학적약물의경구생체내이용효율을증가시키기위한조성물및키트
MXPA99010850A (en) Method and compositions for administering taxanes orally to human patients